Close Menu
Home » David U'Prichard

David U'Prichard

Dec 21, 2006
Premium
Drug developer CoGenesys said that David U’Prichard has been appointed to the company’s board of directors.
 
U’Prichard currently sits on the boards of Invitrogen and SR Pharma, the parent firm of Atugen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Bill to Ease Post-Conviction DNA Testing Access

The Oregon state Senate unanimously passed a bill that would make it easier for people convicted of crimes to initiate DNA testing of evidence, according to the Associated Press.

Ah, Feel Full Now

People reports that researchers have uncovered genetic variants that lead people to always feel full.

Life Insurers, Too, in Florida?

Florida state senators are to weigh a bill prohibiting life insurance companies from using genetic information in coverage decisions, according to Florida Politics.

This Week in Genome Research

In Genome Research this week: metagenomic sequencing assay that detects pathogens in cerebrospinal fluid, single-tube long fragment read approach, and more.

Apr
30
Featured Webinar

Novel Methods for Improving De Novo Transcriptome Annotation with Long-Read Transcript Sequencing

Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
21
Featured Webinar

Implementation of qPCR Mutation Assays for Routine Use in a Hematology/Oncology Lab

Sponsored by
Qiagen

This webinar will provide a first-hand look at how a hematology/oncology lab in the UK set up and validated three molecular assays for routine in-house use.

What's Popular?

In Gene Silencing/Gene Editing

  1. Sherlock Biosciences Closes $31M Series A Financing Round

  2. CRISPR-Cas Base Editing Technology Can Cause Transcriptome-Wide RNA Off-Target Edits

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.